Seviteronel R enantiomer, specifically the VT-464 R enantiomer, is primarily investigated for its potential in treating hormone-dependent cancers, particularly prostate cancer. It functions as a selective inhibitor of CYP17 lyase, an enzyme crucial in the biosynthesis of androgens. By blocking this enzyme, it reduces the production of androgens, which are known to fuel the growth of prostate cancer cells. This makes it a promising candidate for patients with castration-resistant prostate cancer (CRPC), where traditional hormone therapies are no longer effective. Additionally, its enantiomeric specificity may offer improved efficacy and reduced side effects compared to racemic mixtures, enhancing its therapeutic profile in clinical settings.